Physician profile
Peter Golden
NPI 1588867626
$20,592.50
in general payments reported to CMS, 2019-2025
31 companies · $5,213 in 2025
The $5,213 reported for 2025 was more than what 97% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,073 · 2020: $844 · 2021: $1,615 · 2022: $3,126 · 2023: $2,917 · 2024: $4,804 · 2025: $5,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,706.03 |
| Education | $228.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,038.02 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,767.68 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,712.25 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,634.75 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,593.92 | 2021-2025 | |
| Lundbeck LLC | $1,422.39 | 2019-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $1,032.21 | 2022-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $967.37 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $961.05 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $924.05 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $894.80 | 2019-2025 | Trintellix, Vyvanse |
| Sunovion Pharmaceuticals INC. | $819.53 | 2019-2021 | |
| Corium, LLC | $697.87 | 2021-2025 | Azstarys, Azstarys |
| Axsome Therapeutics, INC. | $665.10 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $549.25 | 2019-2025 | Fanapt, Hetlioz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $422.15 | 2022-2024 | Jornay Pm |
| Shire North American Group INC | $268.26 | 2019 | |
| Indivior INC. | $261.31 | 2019-2024 | Perseris |
| Allergan, INC. | $203.31 | 2019-2020 | |
| Noven Therapeutics, LLC | $187.01 | 2022-2025 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $184.21 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $67.05 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $66.58 | 2023-2024 | Quviviq |
| Luye Pharma (USA) Ltd. | $65.39 | 2025 | Erzofri Extended-Release |
| Sage Therapeutics, LLC | $53.96 | 2025 | Zurzuvae |
| Eisai INC. | $40.61 | 2021-2022 | |
| Tempus Ai, INC | $38.61 | 2024 | |
| Neuronetics, INC. | $35.17 | 2022-2023 | Neurostar Tms Therapy System |
| Neos Therapeutics, Lp | $13.42 | 2023 | Adzenys Xr-Odt |
| Tms Neurohealth Centers INC. | $3.99 | 2025 | Tms Neurohealth Centers INC. |
| Validus Pharmaceuticals LLC | $1.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Golden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.